Vemurafenib Plus Cobimetinib in Metastatic Melanoma
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is a single arm explorative phase II clinical trial in 90 subjects with advanced stage
melanoma harbouring a BRAFV600 mutation. PET imaging and molecular diagnostics are combined
in order to monitor response to treatment with vemurafenib plus cobimetinib, examine
development of resistance and correlate changes in metabolic/proliferative activity with
extend of target inhibition.
Phase:
Phase 2
Details
Lead Sponsor:
Netherlands Working Group on Immunotherapy of Oncology
Collaborators:
Hoffmann-La Roche The Netherlands Cancer Institute VU University Medical Center